Treatment Selection in Pulmonary Arterial Hypertension: Phosphodiesterase Type 5 Inhibitors versus Soluble Guanylate Cyclase Stimulator.
Treatment Selection in Pulmonary Arterial Hypertension: Phosphodiesterase Type 5 Inhibitors versus Soluble Guanylate Cyclase Stimulator.
Hiroshi Watanabe
2017 · DOI: 10.15420/ecr.2017:22:2
European Cardiology · 16 Citations
TLDR
The similarities and differences between phosphodiesterase type 5 inhibitors and sGC stimulator based on pharmacological action and clinical trials are discussed, and which is better for the treatment of pulmonary arterial hypertension is considered.